Under the terms of the agreement, Hikma will have rights to sublicense MSD patents and manufacturing know-how for molnupiravir. Hikma will be responsible for manufacturing and commericalising the product. The agreement allows the supply of molnupiravir to 105 low and middle-income countries and Hikma will focus its efforts on the seven MENA markets where it has a presence.

“As a company whose mission is to put better health within reach every day, we are excited to partner with MPP and bring this important COVID-19 medicine to patients in MENA,” said Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA. “This is another example of Hikma’s ongoing commitment to improve access to high-quality, affordable treatments and we look forward to delivering this needed medicine to patients.”

Hikma has worked hard during the pandemic to ensure healthcare professionals in the MENA region have the support they need to care for their patients, particularly during challenging times. This partnership with MPP furthers our work and helps equip doctors and patients in MENA with more treatment options.

About Molnupiravir

Molnupiravir (MK-4482) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several preclinical models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission. Additionally, pre-clinical and clinical data have shown molnupiravir to be active against the most common SARS-CoV-2 variants.

On Dec 23rd 2021, MSD and Ridgeback’s announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for molnupiravir for the Treatment of High-Risk Adults With Mild to Moderate COVID-19